Open letter to the FDA: From priority to dead-end: Why are living donor kidney recipients blocked from novel clinical trials?

American Journal of Transplantation 2026

View at publisher

Authors: Roslyn Bernstein Mannon, Carrie Thiessen, Flavio G. Vincenti

DOI: 10.1016/j.ajt.2026.02.001

Cited by: 0

References: 4

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Organ Donation and Transplantation Statistical Methods in Clinical Trials

References 4